Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial

Hideki Koizumi; Fumi Gomi; Akitaka Tsujikawa; Shigeru Honda; Ryusaburo Mori; Haruka Ochi; Keisuke Iwasaki; Annabelle A. Okada

doi:10.1007/s00417-024-06377-1

March 14, 2024Graefe s Archive for Clinical and Experimental OphthalmologyOpen Access

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

To evaluate 2-year efficacy, durability, and safety of faricimab in the TENAYA Japan subgroup and pooled global TENAYA/LUCERNE cohort of patients with neovascular age-related macular degeneration (nAMD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koizumi et al. (2024) studied this question.

synapsesocial.com/papers/68e74114b6db6435876ba799 https://doi.org/10.1007/s00417-024-06377-1

View Full Paper

Ask AI

Bookmark

Share

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial

Ask about this paper

Abstract

Discussion

Cite This Study

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading